Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Intangibles (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Intangibles for 14 consecutive years, with $163.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles fell 47.81% to $163.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $163.1 million, a 47.81% decrease, with the full-year FY2024 number at $262.4 million, down 24.92% from a year prior.
  • Intangibles was $163.1 million for Q3 2025 at Myriad Genetics, down from $262.4 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $559.9 million in Q1 2021 to a low of $163.1 million in Q3 2025.
  • A 5-year average of $356.1 million and a median of $369.4 million in 2023 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: dropped 6.04% in 2022, then plummeted 47.81% in 2025.
  • Myriad Genetics' Intangibles stood at $404.1 million in 2021, then dropped by 6.04% to $379.7 million in 2022, then fell by 7.95% to $349.5 million in 2023, then dropped by 24.92% to $262.4 million in 2024, then plummeted by 37.84% to $163.1 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Intangibles are $163.1 million (Q3 2025), $262.4 million (Q4 2024), and $312.5 million (Q3 2024).